Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CLDX – Celldex Therapeutics, Inc.

Float Short %

12.06

Margin Of Safety %

Put/Call OI Ratio

1.2

EPS Next Q Diff

-0.07

EPS Last/This Y

-0.96

EPS This/Next Y

-0.85

Price

22.45

Target Price

55.62

Analyst Recom

1.27

Performance Q

10.26

Relative Volume

1.53

Beta

1.19

Ticker: CLDX




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-25CLDX23.360.230.0817857
2025-07-28CLDX22.010.230.4717947
2025-07-29CLDX21.940.231.2017950
2025-07-30CLDX22.810.240.1418071
2025-07-31CLDX21.970.240.0618087
2025-08-01CLDX22.210.240.0018096
2025-08-04CLDX21.790.240.7418117
2025-08-05CLDX22.110.240.1718127
2025-08-06CLDX21.450.240.3418148
2025-08-07CLDX21.180.240.4318175
2025-08-08CLDX20.660.240.0418181
2025-08-11CLDX19.990.230.5618814
2025-08-12CLDX23.810.230.4418690
2025-08-13CLDX24.970.220.0518774
2025-08-14CLDX24.940.230.5118526
2025-08-15CLDX25.50.230.3618513
2025-08-18CLDX24.470.746.144130
2025-08-19CLDX22.310.960.454697
2025-08-20CLDX20.920.952.564738
2025-08-21CLDX21.991.156.075398
2025-08-22CLDX22.461.201.255569
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-25CLDX23.35-55.9-43.1-3.40
2025-07-28CLDX22.11-55.9-16.6-3.40
2025-07-29CLDX21.95-55.9-39.3-3.40
2025-07-30CLDX22.81-55.9-59.3-3.40
2025-07-31CLDX21.98-55.9-23.8-3.40
2025-08-01CLDX22.19-55.9-45.2-3.40
2025-08-04CLDX21.80-55.9-32.3-3.40
2025-08-05CLDX22.13-55.9-47.8-3.40
2025-08-06CLDX21.44-55.9-25.9-3.40
2025-08-07CLDX21.21-55.9-35.4-3.40
2025-08-08CLDX20.66-55.9-27.9-3.40
2025-08-11CLDX19.98-55.9-7.1-3.40
2025-08-12CLDX23.81-39.2-115.4-3.41
2025-08-13CLDX24.99-39.2-48.0-3.41
2025-08-14CLDX24.94-39.2-25.6-3.41
2025-08-15CLDX25.50-39.0-35.9-3.41
2025-08-18CLDX24.47-39.0-9.7-3.41
2025-08-19CLDX24.02-39.0-18.3-3.41
2025-08-20CLDX20.91-39.029.3-3.41
2025-08-21CLDX21.98-39.0-51.3-3.41
2025-08-22CLDX22.45-39.0-35.5-3.41
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-25CLDX0.00-3.4113.13
2025-07-28CLDX0.00-3.6713.13
2025-07-29CLDX0.00-3.6713.13
2025-07-30CLDX0.00-3.6713.13
2025-07-31CLDX0.00-3.6713.13
2025-08-01CLDX0.00-3.6713.13
2025-08-04CLDX0.00-2.7913.13
2025-08-05CLDX0.00-2.7913.13
2025-08-06CLDX0.00-2.7913.13
2025-08-07CLDX0.00-2.7913.13
2025-08-08CLDX0.00-2.7913.13
2025-08-11CLDX0.00-2.7913.13
2025-08-12CLDX0.00-2.7912.06
2025-08-13CLDX0.00-2.7912.06
2025-08-14CLDX0.00-2.7912.06
2025-08-15CLDX-0.04-2.7912.06
2025-08-18CLDX-0.04-1.8412.06
2025-08-19CLDX-0.04-1.8412.06
2025-08-20CLDX-0.04-1.8412.06
2025-08-21CLDX-0.04-1.8412.06
2025-08-22CLDX-0.04-1.8412.06
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.85

Avg. EPS Est. Current Quarter

-0.89

Avg. EPS Est. Next Quarter

-0.92

Insider Transactions

-0.04

Institutional Transactions

-1.84

Beta

1.19

Average Sales Estimate Current Quarter

1

Average Sales Estimate Next Quarter

1

Fair Value

Quality Score

22

Growth Score

36

Sentiment Score

2

Actual DrawDown %

60.7

Max Drawdown 5-Year %

-73.1

Target Price

55.62

P/E

Forward P/E

PEG

P/S

257.6

P/B

2.28

P/Free Cash Flow

EPS

-3.01

Average EPS Est. Cur. Y​

-3.41

EPS Next Y. (Est.)

-4.26

Target Price Estimates Raised

Target Price Estimates Lowered

2

Profit Margin

-3446.88

Relative Volume

1.53

Return on Equity vs Sector %

-55.1

Return on Equity vs Industry %

-42.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

-35.5
Celldex Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 186
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its clinical development programs are Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias, prurigo nodularis, eosinophilic esophagitis, and atopic dermatitis; and CDX-622, a bispecific candidate for inflammatory diseases, which targets two complementary pathways that drive chronic inflammation, potently neutralizing the alarmin thymic stromal lymphopoietin and depleting mast cells through stem cell factor starvation. The company is headquartered in Hampton, New Jersey.
stock quote shares CLDX – Celldex Therapeutics, Inc. Stock Price stock today
news today CLDX – Celldex Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLDX – Celldex Therapeutics, Inc. yahoo finance google finance
stock history CLDX – Celldex Therapeutics, Inc. invest stock market
stock prices CLDX premarket after hours
ticker CLDX fair value insiders trading